FrancophonIA/ELRC3.0 huggingface dataset:
English: Adequate medical treatment and provisions should be available for immediate use for a potential anaphylactic reaction, especially for patients with a history of allergic reactions.
Croatian: Na raspolaganju treba biti primjerena medicinska terapija i sredstva za hitnu primjenu u slučaju potencijalne anafilaktičke reakcije, posebno za bolesnike s anamnezom alergijskih reakcija.
English: Treatment of bleeding episodes (On demand treatment)
Croatian: Liječenje epizoda krvarenja (liječenje prema potrebi)
English: You can store the reconstituted product at room temperature not to exceed 25° C for up to three hours.
Croatian: Rekonstituirani lijek možete čuvati na sobnoj temperaturi ne višoj od 25 °C do najviše tri sata.
English: Grip the package at its edge and lift it off the Mix2Vial device.
Croatian: Uhvatite pakiranje za rub i podignite ga s uređaja Mix2Vial.
English: Fertility The effects of VEYVONDI on fertility have not been established.
Croatian: Plodnost Učinci lijeka VEYVONDI na plodnost nisu ustanovljene.
English: These could be early symptoms of a hypersensitivity reaction.
Croatian: To mogu biti rani simptomi reakcije preosjetljivosti.
English: Manufacturer Baxter AG Industriestraße 67 A-1221 Vienna Austria
Croatian: Proizvođač Baxter AG Industriestraße 67 A-1221 Beč Austrija
English: If you have previously been treated with plasma-derived VWF concentrates you may have reduced response to VEYVONDI due to pre-existing antibodies.
Croatian: Ako ste prethodno liječeni koncentratima VWF-a dobivenima iz plazme, možda ćete imati smanjen odgovor na VEYVONDI zbog već postojećih antitijela.
English: 8 Draw air into the empty, sterile disposable plastic syringe by pulling back on the plunger.
Croatian: 8 Uvucite zrak u praznu, sterilnu jednokratnu plastičnu štrcaljku povlačeći klip unatrag.
English: A total of 92 unique subjects (80 unique subjects with VWD in studies 070701, 071001 and 071101 and 12 subjects with Haemophilia A in study 071104) were exposed to VEYVONDI during clinical development.
Croatian: Ukupno je 92 pojedinačna ispitanika (80 pojedinačnih ispitanika s VWD-om u ispitivanjima 070701, 071001 i 071101 te 12 ispitanika s hemofilijom A u ispitivanju 071104) bilo izloženo lijeku VEYVONDI tijekom kliničkog razvoja.
English: VWF is the carrier molecule for coagulation factor VIII and is involved in blood clotting making platelets stick to wounds and so helps to form a blood clot.
Croatian: VWF je molekula nosač koagulacijskog faktora VIII i sudjeluje u zgrušavanju krvi tako što dovodi do nakupljanja trombocita u ranama, pa na taj način pomaže u stvaranju krvnog ugruška.
English: In patients with high levels of anti-VWF antibodies, von Willebrand factor therapy may not be effective and other therapeutic options should be considered.
Croatian: U bolesnika s visokim razinama antitijela na VWF, terapija von Willebrandovim faktorom možda neće biti učinkovita te je potrebno razmotriti druge terapijske opcije.
English: The first dose of VEYVONDI should be 40 to 80 IU/kg body weight.
Croatian: Prva doza lijeka VEYVONDI treba biti 40 do 80 IU/kg tjelesne mase.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with VEYVONDI in all subsets of the paediatric population in the treatment of von Willebrand Disease (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka VEYVONDI u svim podskupinama pedijatrijske populacije u liječenju von Willebrandove bolesti (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Shelf-life after reconstitution:
Croatian: Vijek trajanja nakon rekonstitucije:
English: Calculation of rVWF dose (to be administered within 1 hour prior to surgery) (IU VWF:RCo required)
Croatian: Izračun doze rVWF (koju treba primijeniti unutar 1 sata prije kirurškog zahvata) (potrebne IU VWF:RCo)
English: Haemostasis cannot be ensured until Factor VIII coagulant activity (FVIII:C) is at least 0.4 IU/mL (≥ 40% of normal activity).
Croatian: Hemostaza se ne može osigurati dok koagulacijska aktivnost faktora VIII (FVIII:C) ne dosegne najmanje 0,4 IU/ml (≥ 40% normalne aktivnosti).
English: Hypersensitivity reactions (including anaphylaxis) may occur.
Croatian: Mogu se pojaviti reakcije preosjetljivosti (uključujući anafilaksiju).
English: Use the reconstituted product (after mixing the powder with the supplied water) as soon as possible and within three hours.
Croatian: Primijenite rekonstituirani lijek (nakon miješanja praška s priloženom vodom) što je prije moguće i unutar tri sata.
English: Mean (95% CI) SD
Croatian: Srednja (95% CI) SD
English: Steps
Croatian: Koraci
English: VEYVONDI has no or negligible influence on the ability to drive and use machines.
Croatian: VEYVONDI ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada na strojevima.
English: - Do not mix vonicog alfa with other medicinal products except for rFVIII.
Croatian: - Nemojte miješati vonikog alfa s drugim lijekovima osim s rFVIII.
English: Von Willebrand disease is an inherited bleeding disorder caused by the lack or an insufficient amount of von Willebrand factor.
Croatian: Von Willebrandova bolest nasljedni je poremećaj krvarenja uzrokovan nedostatkom ili nedovoljnom količinom von Willebrandova faktora.
English: If flakes or particles are seen, do not use the solution and notify your doctor.
Croatian: Ako zapazite pahuljice ili čestice, nemojte primjenjivati otopinu i obavijestite svojeg liječnika.
English: For comfort, a winged (butterfly) infusion set is preferred.
Croatian: Radi udobnosti preporučuje se set za infuziju s krilcima (leptir).
English: - Use the reconstituted product (after mixing the powder with the supplied water) as soon as possible and within three hours.
Croatian: - Primijenite rekonstituirani lijek (nakon miješanja praška s priloženom vodom) što je prije moguće i unutar tri sata.
English: If any of these symptoms occur, stop the infusion immediately and contact your doctor.
Croatian: Ako se pojavi bilo koji od navedenih simptoma, odmah prekinite primjenu infuzije i obratite se svom liječniku.
English: - Do not use this medicine after the expiry date which is stated on the label after EXP.
Croatian: - Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici iza oznake EXP.
English: VEYVONDI is for intravenous use.
Croatian: VEYVONDI je za intravensku primjenu.
English: Point the needle up and remove any air bubbles by gently tapping the syringe with your finger and slowly and carefully pushing air out of the syringe and needle.
Croatian: Usmjerite iglu prema gore i uklonite moguće mjehuriće zraka laganim lupkanjem štrcaljke prstom te polako i pažljivo istisnite zrak iz štrcaljke i igle.
English: 3 Open the Mix2Vial device package by completely peeling away the lid, without touching the inside of the package.
Croatian: 3 Otvorite pakiranje uređaja Mix2Vial tako da potpuno odlijepite pokrov ne dirajući unutrašnjost pakiranja.
English: During and After Surgery:
Croatian: Tijekom i nakon kirurškog zahvata:
English: During and After Surgery
Croatian: Tijekom i nakon kirurškog zahvata
English: - If your bleeding is not controlled with VEYVONDI, tell your doctor immediately.
Croatian: - Ako se Vaše krvarenje ne može kontrolirati pomoću lijeka VEYVONDI, odmah se obratite liječniku.
English: Do not mix VEYVONDI with other medicinal products except for rFVIII.
Croatian: Nemojte miješati VEYVONDI s drugim lijekovima osim s rFVIII.
English: If you infuse more VEYVONDI than recommended, tell your doctor as soon as possible.
Croatian: U slučaju da ste infuzijom primijenili više lijeka VEYVONDI nego što je preporučeno, obavijestite svog liječnika što je prije moguće.
English: Major b
Croatian: Veće b
English: e[(h*IU/dL)/(IU VWF:RCo/kg)] f[VWF:RCo assays with different sensitivity and working ranges were used: Phase 1: automated assay 0.081.50 IU/mL and sensitive manual assay 0.01 - 0.08 IU/mL; Phase 3: automated assay 0.08 - 1.50 IU/mL g This trial was done using ADVATE, a recombinant factor VIII
Croatian: e[(h*IU/dl)/(IU VWF:RCo/kg)] [Korišteni su VWF:RCo testovi s različitom osjetljivošću i radnim rasponima: Faza 1: automatizirani test 0,08-1,50 IU/ml i osjetljiv ručni test 0,01 - 0,08 IU/ml; Faza 3: automatizirani test 0,081,50 IU/ml g
English: One of the 80 subjects who received VEYVONDI peri-operatively in clinical studies developed treatment-emergent binding antibodies against VWF following a surgery for whom no adverse events or lack of haemostatic efficacy has been reported.
Croatian: Jedan od 80 ispitanika koji su primali VEYVONDI perioperativno u kliničkim ispitivanjima razvio je liječenjem uzrokovana vezujuća antitijela na VWF-a nakon kirurškog zahvata za kojeg nisu prijavljeni nikakvi štetni događaji ili nedostatak hemostatske djelotvornosti.
English: Number and Frequency by Subject a
Croatian: Broj i učestalost po ispitaniku a
English: If your dose requires multiple syringes, attach and administer each additional syringe of VEYVONDI one at a time.
Croatian: Ako je za Vašu dozu potrebno više štrcaljki, spojite i primijenite svaku dodatnu štrcaljku lijeka VEYVONDI jednu po jednu.
English: In actively bleeding patients it is recommended to co-administer a FVIII product with VEYVONDI as a first line treatment and depending on the FVIII activity levels (see section 4.2).
Croatian: U bolesnika s aktivnim krvarenjem preporučuje se istovremena primjena FVIII s lijekom VEYVONDI kao prva linija terapije i ovisno o razinama aktivnosti FVIII (vidjeti dio 4.2).
English: There may be a risk of developing blood clots (thrombosis) in case of an accidental high dose.
Croatian: Postoji opasnost od pojave krvnih ugršaka (tromboza) u slučaju nehotične primjene visoke doze.
English: After 72 hours post surgery
Croatian: Poslije 72 sata nakon kirurškog zahvata
English: In major bleeding episodes, maintain trough levels of VWF:RCo greater than 50% for as long as deemed necessary.
Croatian: Pri epizodama većeg krvarenja, održavajte najniže razine VWF:RCo veće od 50% dok god je to klinički potrebno.
English: VEYVONDI is used to treat and control bleeding episodes and to prevent bleeding during surgery in adult patients (aged 18 years and older) with von Willebrand disease.
Croatian: VEYVONDI se koristi za liječenje i kontrolu epizoda krvarenja te za sprečavanje krvarenja tijekom kirurških zahvata u odraslih bolesnika (u dobi od 18 godina i više) s von Willebrandovom bolešću.
English: Detailed instructions for reconstitution and admnistration are given at the end of this package leaflet.
Croatian: Detaljne upute za rekonstituciju i primjenu navedene su na kraju ove upute o lijeku
English: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Croatian: Kako bi se poboljšala sljedivost bioloških lijekova, naziv lijeka i broj serije primijenjenog lijeka moraju biti jasno evidentirani.
English: It is strongly recommended that every time that VEYVONDI is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Croatian: Izrazito se preporučuje da se prilikom svake primjene lijeka VEYVONDI bolesniku, evidentira ime bolesnika i broj serije lijeka kako bi se održala poveznica između bolesnika i serije lijeka.
English: Treatment of VWD patients who have high-titer binding antibodies (due to previous treatment with pdVWF) may require a higher dose to overcome the binding antibody effect and such patients could be managed clinically by administration of higher doses of vonicog alfa based on the PK data for each individual patient.
Croatian: U liječenju bolesnika s VWD-om koji imaju vezujuća antitijela visokog titra (zbog prethodnog liječenja s VWF dobivenim iz plazme) možda će biti potrebna viša doza kako bi se prevladao učinak vezujućih antitijela, a kliničko stanje takvih bolesnika može se liječiti primjenom viših doza vonikoga alfa na temelju PK podataka za svakog pojedinog bolesnika.
English: Your doctor may test your blood to make sure that you have adequate levels of von Willebrand factor.
Croatian: Vaš liječnik može testirati vašu krv kako bi bio siguran da imate dovoljne razine von Willebrandova faktora.
English: The contents of each vial of rVWF and rFVIII can be drawn into a single syringe by using a separate unused reconstitution device (see 6.2 for incompatibilities).
Croatian: Sadržaj pojedinačne bočice rVWF i rFVIII može se uvući u istu štrcaljku pomoću zasebnog, novog uređaja za rekonstituciju (vidjeti 6.2 za inkompatibilnosti).
English: (IU VWF:RCo/kg body weight)
Croatian: (IU VWF:RCo/kg tjelesne mase)
English: What you need to know before you use VEYVONDI Do not use VEYVONDI: - if you are allergic to vonicog alfa or any of the other ingredients of this medicine (listed in section 6) - if you are allergic to mouse or hamster proteins If you are unsure about this, ask your doctor.
Croatian: Što morate znati prije nego počnete primjenjivati VEYVONDI Nemojte primjenjivati VEYVONDI: - ako ste alergični na vonikog alfa ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako ste alergični na bjelančevine miša ili hrčka Ako imate dvojbe, obratite se svom liječniku.
English: It behaves in the same way as natural human von Willebrand factor (VWF) in the body.
Croatian: Ponaša se jednako kao i prirodni ljudski von Willebrandov faktor (VWF) u tijelu.
English: 50 to 80 IU/kg
Croatian: 50 do 80 IU/kg
English: An exploratory analysis of combined data from studies 070701 and 071001 indicated a statistically significantly (at the 5% level) longer mean residence time, a statistically significantly (at the 5% level) longer terminal half-life and statistically significantly (at the 5% level) larger AUC0-inf regarding VWF:RCo following administration with VEYVONDI (50 IU/kg VWF:RCo) and combined administration of VEYVONDI and octocog alfa (50 IU/kg VWF:RCo and 38.5 IU/kg rFVIII) than after administration of pdVWF and pdFVIII (50 IU/kg pdVWF:RCo and 38.5 IU/kg pdFVIII).
Croatian: Eksplorativna analiza kombiniranih podataka iz ispitivanja 070701 i 071001 pokazala je statistički značajnije (pri razini od 5%) dulje srednje vrijeme zadržavanja, statistički značajniji (pri razini od 5%) dulji terminalni poluvijek i statistički značajniji (pri razini od 5%) veći AUC0-inf u pogledu VWF:RCo nakon primjene s lijekom VEYVONDI (50 IU/kg VWF:RCo) i kombinirane primjene lijeka VEYVONDI i oktokoga alfa (50 IU/kg VWF:RCo i 38,5 IU/kg rFVIII) nego nakon primjene VWF dobivenog iz plazme i FVIII dobivenog iz plazme (50 IU/kg iz plazme dobivenog VWF:Rco i 38,5 IU/kg iz plazme dobivenog FVIII).
English: Reconstituted product should not be refrigerated.
Croatian: Rekonstituirani lijek ne smije se odlagati u hladnjak.
English: Up to 72 hours post surgery
Croatian: Do 72 sata nakon kirurškog zahvata
English: During treatment with VEYVONDI the following adverse reactions may occur: Hypersensitivity or allergic reactions, thromboembolic events, inhibitor formation against VWF.
Croatian: Tijekom liječenja lijekom VEYVONDI, mogu se javiti sljedeće nuspojave: preosjetljivost ili alergijske reakcije, tromboembolijski događaji, stvaranje inhibitora VWF-a.
English: After reconstitution For storage conditions after reconstitution of the medicinal product, see section 6.3.
Croatian: Nakon rekonstitucije Uvjete čuvanja nakon rekonstitucije lijeka vidjeti u dijelu 6.3.
English: When coadministration of rVWF and rFVIII is considered necessary, they can be pre-mixed in a single syringe to achieve the appropriate dose.
Croatian: Ako se smatra da je nužna istovremena primjena rVWF i rFVIII, mogu se pomiješati u istoj štrcaljki kako bi se dobila odgovarajuća doza.
English: After reconstitution, when drawn into the syringe, the solution is clear, colourless in appearance and free from flakes or other foreign particles.
Croatian: Nakon rekonstitucije, pri uvlačenju u štrcaljku, otopina je bistra, bezbojna i bez pahuljica ili drugih stranih čestica.
English: If recombinant factor VIII has been prescribed, administer recombinant factor VIII within 10 minutes after infusion of VEYVONDI has been completed.
Croatian: Ako je Vaš liječnik propisao rekombinantni faktor VIII, primijenite rekombinantni faktor VIII unutar 10 minuta od završetka infuzije lijeka VEYVONDI.
English: Prevention of bleeding/haemorrhage and treatment in case of elective surgery
Croatian: Sprječavanje krvarenja/hemoragije i liječenje u slučaju elektivnog kirurškog zahvata
English: In clinical trials, one case of clinically asymptomatic deep vein thrombosis (DVT) was reported for a subject in the surgery study who had total hip replacement.
Croatian: U kliničkim ispitivanjima prijavljen je jedan klinički asimptomatski slučaj duboke venske tromboze (DVT) u ispitivanju kirurškog zahvata kod ispitanika s totalnom protezom kuka.
English: Do not increase the total dose of VEYVONDI to control your bleeding without consulting your doctor.
Croatian: Nemojte povećavati ukupnu dozu lijeka VEYVONDI kako biste kontrolirali krvarenje ako o tome niste razgovarali sa svojim liječnikom.
English: Generally, 1 IU/kg (VWF:RCo/VEYVONDI/vonicog alfa) raises the plasma VWF:RCo by 0.02 IU/mL (2%).
Croatian: Općenito, 1 IU/kg (VWF:RCo/VEYVONDI/vonikog alfa) povećava razinu VWF:RCo u plazmi za 0,02 IU/ml (2%).
English: 12 Do not push and pull solution back and forth between syringe and vial.
Croatian: 12 Nemojte potiskivati i povlačiti otopinu unutra pa van između štrcaljke i bočice.
English: Subsequent infusions
Croatian: Naknadne infuzije
English: For prevention of excessive bleeding in case of elective surgery, within 3 hours prior to initiation of any surgical procedure, the FVIII:C levels should be assessed.
Croatian: Za sprečavanje prekomjernog krvarenja u slučaju elektivnog kirurškog zahvata unutar 3 sata prije započinjanja bilo kojeg kirurškog zahvata treba procijeniti razine FVIII:C.
English: If any reaction, such as tachycardia, occurs that might be related to the administration of the product, the rate of infusion should be reduced or stopped as required by the clinical condition of the patient.
Croatian: U slučaju pojave bilo kakve reakcije, primjerice tahikardije, koja može biti povezana s primjenom lijeka, treba smanjiti brzinu infuzije ili prekinuti infuziju u skladu s kliničkim stanjem bolesnika.
English: Replacement levels of VWF:RCo > 0.6 IU/mL (60%) and FVIII:C > 0.4 IU/mL (40%) should be achieved.
Croatian: Potrebno je postići nadomjesne razine od VWF:RCo > 0,6 IU/ml (60%) i FVIII:C > 0,4 IU/ml (40%).
English: Depending on the patient's baseline FVIII:C levels, a single infusion of rVWF will, in a majority of patients, lead to an increase above 40% in endogenous FVIII:C activity within 6 hours and will result in sustaining this level up to 72 hours post infusion.
Croatian: Ovisno o bolesnikovim početnim razinama FVIII:C, jedna infuzija rVWF-a će, kod većine bolesnika, dovesti do povećanja iznad 40% u endogenoj aktivnosti FVIII:C u roku od 6 sati te će rezultirati održavanjem te razine do 72 sata nakon infuzije.
English: Binding antibodies against impurities such as rFurin, CHO-protein or mouse IgG were not observed after treatment with VEYVONDI.
Croatian: Vezujuća antitijela na nečistoće kao što su rFurin, CHO-protein ili mišji IgG nisu uočena nakon liječenja lijekom VEYVONDI.
English: Table 4 Summary of Adverse Reactions reported in Clinical Trials with VEYVONDI in von Willebrand Disease
Croatian: Tablica 4 Sažetak nuspojava prijavljenih u kliničkim ispitivanjima lijeka VEYVONDI kod von Willebrandove bolesti
English: The rFVIII dose should be calculated according to the difference between the patient's baseline plasma FVIII:C level, and the desired peak FVIII:C level to achieve an appropriate plasma FVIII:C level based on the approximate mean recovery of 0.02 (IU/mL)/(IU/kg).
Croatian: Doza rFVIII treba se izračunati prema razlici između početne razine FVIII:C u plazmi bolesnika i željene vršne razine FVIII:C kako bi se ostvarila odgovarajuća razina FVIII:C u plazmi na temelju približne srednje vrijednosti oporavka od 0,02 (IU/ml)/(IU/kg).
English: The powder is a white to off-white lyophilized powder The solvent is a clear and colourless solution.
Croatian: Prašak je bijeli do bjelkasti liofilizirani prašak Otapalo je bistra i bezbojna otopina.
English: Dosing guidelines for treatment of minor and major haemorrhages are provided in Table 1.
Croatian: Upute za doziranje za liječenje manjih i većih krvarenja navedene su u Tablici 1.
English: No treatment-emergent development of neutralizing antibodies against human VWF or neutralizing antibodies against human rFVIII was observed.
Croatian: Nije uočen liječenjem uzrokovan razvoj neutralizirajućih antitijela na ljudski VWF ili neutralizirajućih antitijela na ljudski rFVIII.
English: Do not stop using VEYVONDI without consulting your doctor.
Croatian: Ne prekidajte primjenu lijeka VEYVONDI bez savjetovanja sa svojim liječnikom.
English: Please refer to Table 3 for treatment recommendations for subsequent maintenance doses.
Croatian: Pogledajte Tablicu 3 za preporuke za terapiju naknadnim dozama održavanja.
English: Therefore, patients at risk have to be monitored for early signs of thrombosis, and prophylaxis measures against thromboembolism should be instituted according to current recommendations and standard of care.
Croatian: Stoga rizične bolesnike treba pratiti kako bi se uočila pojava ranih znakova tromboze te je potrebno uvesti mjere za profilaksu tromboembolije u skladu s važećim preporukama i standardnom skrbi.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Intravenous use, after reconstitution.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Za intravensku primjenu, nakon rekonstitucije.
English: Known allergic reaction to mouse or hamster proteins.
Croatian: Poznate alergijske reakcije na bjelančevine miša ili hrčka.
English: Slowly infuse VEYVONDI.
Croatian: Polako infuzijom primijenite VEYVONDI.
English: It is not uncommon for a few flakes or particles to remain in the product vial after reconstitution.
Croatian: Nije neuobičajena pojava nekoliko pahuljica ili čestica u bočici lijeka nakon rekonstitucije.
English: - Do not refrigerate the solution after preparation.
Croatian: - Ne odlažite otopinu u hladnjak nakon pripreme.
English: VEYVONDI contains trace amounts of recombinant coagulation factor VIII.
Croatian: VEYVONDI u tragovima sadrži rekombinantni koagulacijski faktor VIII.
English: The complete dose of VEYVONDI should be administered followed by rFVIII within 10 minutes.
Croatian: Cijela doza lijeka VEYVONDI treba se primijeniti, a potom u roku od 10 minuta treba primijeniti rFVIII.
English: Administration of VEYVONDI allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency (von Willebrand's disease) at two levels: - VEYVONDI re-establishes platelet adhesion to the vascular sub-endothelium at the site of vascular damage (as it binds both to the vascular sub-endothelium matrix (e.g. collagen) and to the platelet membrane), providing primary haemostasis as shown by the shortening of the bleeding time.
Croatian: Primjena lijeka VEYVONDI omogućuje korekciju hemostatskih abnormalnosti koje se javljaju u bolesnika s nedostatkom von Willebrandova faktora (von Willebrandova bolest) na dvije razine: - VEYVONDI ponovno uspostavlja adheziju trombocita na vaskularni subendotel na mjestu oštećenja žile (jer se veže i na matricu žilnog subendotela (npr. kolagen) i na membranu trombocita), pružajući primarnu hemostazu na što ukazuje skraćivanje vremena krvarenja.
English: VEYVONDI contains trace amounts of mouse immunoglobulin G (MuIgG) and Hamster proteins (less than or equal to 2 ng/IU VEYVONDI).
Croatian: VEYVONDI u tragovima sadrži mišji imunoglobulin G (MuIgG) i proteine hrčka (manje ili jednako 2 ng/IU lijeka VEYVONDI).